Stockscreener 앱 받기
32.48
4.81%
1.49
시간 외 거래:
32.98
0.50
+1.54%
전일 마감가:
$30.99
열려 있는:
$31.05
하루 거래량:
2.17M
Relative Volume:
1.04
시가총액:
$3.34B
수익:
$164.01M
순이익/손실:
$-65.04M
주가수익비율:
-47.28
EPS:
-0.687
순현금흐름:
$-383.84M
1주 성능:
+10.14%
1개월 성능:
+16.29%
6개월 성능:
+26.87%
1년 성능:
+94.84%
1일 변동 폭
$30.91
$34.19
1주일 범위
$28.67
$34.19
52주 변동 폭
$15.60
$36.44
빔 테라퓨틱스 Stock (BEAM) Company Profile
명칭
Beam Therapeutics Inc
전화
857-327-8775
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
32.48 | 3.20B | 164.01M | -65.04M | -383.84M | -0.687 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
빔 테라퓨틱스 Stock (BEAM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-20 | 개시 | Canaccord Genuity | Buy |
| 2025-10-09 | 개시 | Jefferies | Buy |
| 2025-03-28 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-10 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-23 | 개시 | H.C. Wainwright | Buy |
| 2024-01-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-10-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 개시 | Citigroup | Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-01-05 | 개시 | Guggenheim | Buy |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-09-24 | 재개 | Stifel | Buy |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Redburn | Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 개시 | Wells Fargo | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-08-05 | 개시 | William Blair | Outperform |
| 2020-03-02 | 개시 | Barclays | Overweight |
| 2020-03-02 | 개시 | JP Morgan | Overweight |
| 2020-03-02 | 개시 | Jefferies | Buy |
| 2020-03-02 | 개시 | Wedbush | Outperform |
모두보기
빔 테라퓨틱스 주식(BEAM)의 최신 뉴스
5 Best Genomics Stocks to Buy According to Analysts - Insider Monkey
BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data - Stocktwits
Precision Trading with Beam Therapeutics Inc. (BEAM) Risk Zones - Stock Traders Daily
BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
BEAM Stock Price, Quote & Chart - ChartMill
Amova Asset Management Americas Inc. Cuts Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Geode Capital Management LLC Sells 39,035 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics (Nasdaq: BEAM) shareholders approve directors, auditor and pay - Stock Titan
Beam Therapeutics Inc (BEAM) Stock Price, Quote, News & History - Benzinga
Beam Therapeutics (BEAM) director receives 19,676-share option grant - Stock Titan
Beam Therapeutics (BEAM) director receives stock options grant for 19,676 shares - Stock Titan
Beam Therapeutics (BEAM) grants 19,676 stock options to director - Stock Titan
Beam Therapeutics (BEAM) director receives stock options on 19,676 shares - Stock Titan
Beam Therapeutics (BEAM) awards stock options to director Chirfi - Stock Titan
Beam Therapeutics (BEAM) awards director Graham Cooper 19,676 options - Stock Titan
Bethany Cavanagh (Beam Therapeutics) sells $79,688 in BEAM stock - Investing.com
Beam Therapeutics (NASDAQ:BEAM) Trading 10.1% HigherWhat's Next? - MarketBeat
Wells Fargo Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $70 - Moomoo
Beam Therapeutics CEO Evans sells $739k in stock - Investing.com
BEAM Technical Analysis & Stock Price Forecast - Intellectia AI
Beam Therapeutics Stock Hits Day Low of $28.80 Amid Price Pressure - Markets Mojo
Beam Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Technical Reactions to BEAM Trends in Macro Strategies - Stock Traders Daily
Draft FDA guidance could be a boon for gene therapy developers - Seeking Alpha
Beam Therapeutics eyes sickle cell BLA as Alpha-1 gene-editing program advances - MSN
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? - AOL.com
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum - Quantisnow
Beam Therapeutics (BEAM) Is Up 17.6% After Advancing BEAM-302 Toward Accelerated Approval in AATD - Yahoo Finance
Gene Editing Sector Gains Momentum with Key Players CRISPR and Beam - Intellectia AI
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? - The Motley Fool
What Were the Key Highlights from Beam's RBC Conference Presentation - Kavout
ADAR1 Capital Management, LLC's Beam Therapeutics Inc(BEAM) Holding History - GuruFocus
Trading the Move, Not the Narrative: (BEAM) Edition - Stock Traders Daily
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com UK
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy By Investing.com - Investing.com South Africa
CCORF Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $75 - Moomoo
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Beam Therapeutics Inc. (BEAM) Presents at ATS 2026 International ConferenceSlideshow - Seeking Alpha
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances - Barchart.com
BEAM: Lead gene editing programs advance toward approval with strong efficacy, safety, and payer value - TradingView
Beam Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Two Programs That Could Make or Break Beam Therapeutics Inc (BEAM) Stock - Insider Monkey
In Vivo Gene Editing Market is expected to Hit US$ 37.75 Billion - openPR.com
10 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Beam Therapeutics (BEAM) Is Down 12.0% After Narrowing Losses And Positive BEAM-302 Data Update – Has The Bull Case Changed? - Sahm
Beam Therapeutics Data Puts BEAM 302 And AAT Disease In Focus - Yahoo Finance
Beam Therapeutics (BEAM) Advances Phase 1/2 Trial for AAT Deficiency - GuruFocus
Verve Therapeutics : VERV - 24/7 Wall St.
Beam Therapeutics presents AATD gene therapy trial data at ATS - Investing.com UK
빔 테라퓨틱스 (BEAM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
빔 테라퓨틱스 주식 (BEAM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Evans John M. | CEO |
Apr 01 '26 |
Sale |
24.58 |
30,078 |
739,317 |
1,047,205 |
| Simon Amy | Chief Medical Officer |
Apr 01 '26 |
Sale |
24.58 |
6,700 |
164,686 |
102,735 |
| Cavanagh Bethany J | SVP, Finance and Treasurer |
Apr 01 '26 |
Sale |
24.58 |
3,242 |
79,688 |
51,171 |
| Bellon Christine | Chief Legal Officer |
Apr 01 '26 |
Sale |
24.58 |
5,956 |
146,398 |
109,711 |
| Ciaramella Giuseppe | President |
Apr 01 '26 |
Sale |
24.58 |
11,810 |
290,290 |
218,406 |
| Evans John M. | CEO |
Mar 30 '26 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Mar 31 '26 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Mar 31 '26 |
Sale |
22.76 |
25,000 |
569,085 |
986,667 |
| Evans John M. | CEO |
Mar 30 '26 |
Sale |
22.37 |
25,000 |
559,230 |
986,667 |
2.60%
0.94%
자본화:
|
볼륨(24시간):